Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Germ Cell and Embryonal 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1

Interventions

Sunitinib 3trastuzumab deruxtecan 1ripretinib 1guadecitabine 1Thalidomide 1Specimen Handling 1Sodium Chloride 1Psychiatric Rehabilitation 1OSI 930 1Nivolumab 1Midazolam 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Fentanyl 1Erlotinib Hydrochloride 1Early Intervention, Educational 1Docetaxel 1Counseling 1Caffeine 1CTLA-4 Antigen 17-hydroxystaurosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × guadecitabine × Genitourinary × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡